The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study
- PMID: 23219372
- DOI: 10.1016/j.eururo.2012.11.050
The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study
Abstract
Background: Few studies have discussed the prognostic impact of serum C-reactive protein (CRP) level in upper tract urothelial carcinoma (UTUC).
Objective: To investigate whether the perioperative level of CRP provides additional prognostic information following radical nephroureterectomy (RNU).
Design, setting, and participants: A total of 564 patients with UTUC from a retrospective multi-institutional cohort were included. The median follow-up was 32 mo.
Intervention: All patients underwent RNU without neoadjuvant chemotherapy, while 106 patients (18.8%) received adjuvant chemotherapy.
Outcome measurements and statistical analysis: Associations between perioperative CRP level and outcome were assessed using multivariate analysis. A serum CRP level >0.50mg/dl was defined as elevated.
Results and limitations: Preoperative CRP (pre-CRP) level was elevated in 136 patients (24.1%). Multivariate analysis showed that pre-CRP elevation was an independent predictor of subsequent disease recurrence (hazard ratio [HR]: 1.47 for CRP 0.51-2.00; HR: 1.89 for CRP >2.00). Five-year recurrence-free survival rates were 69.2% in patients with pre-CRP levels ≤ 0.50 mg/dl, 54.3% in patients with pre-CRP levels between 0.51 and 2.00 mg/dl, and 35.4% in patients with pre-CRP levels >2.00 mg/dl (p<0.001). Similar results were found in cancer-specific mortality, showing that pre-CRP elevation was an independent predictor of worse outcome (HR: 1.74 for CRP 0.51-2.00; HR: 2.31 for CRP >2.00). In a subgroup analysis of the elevated pre-CRP group, postoperative normalisation of CRP level was an independent predictor of better outcome. This study is limited by its retrospective nature as well as its heterogeneous group of patients and variable follow-up protocols resulting from the multi-institution design.
Conclusions: Serum CRP may become a possible biomarker in UTUC, suggesting that patients with an elevated pre-CRP level could be predicted to have subsequent disease recurrence and cancer-specific mortality, while postoperative normalisation of CRP level was an independent predictor for prognosis.
Keywords: C-reactive protein; Outcome; Survival; Upper urinary tract; Urothelial carcinoma.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Similar articles
-
C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.Urol Oncol. 2013 Nov;31(8):1725-30. doi: 10.1016/j.urolonc.2012.05.008. Epub 2012 Nov 8. Urol Oncol. 2013. PMID: 23141922
-
Prognostic value of plasma fibrinogen levels in patients with localized upper tract urothelial carcinoma.BJU Int. 2013 May;111(6):857-64. doi: 10.1111/j.1464-410X.2012.11353.x. Epub 2012 Jul 3. BJU Int. 2013. PMID: 22757942
-
Preoperative C-reactive protein in the serum: a prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.Urol Int. 2014;93(3):352-60. doi: 10.1159/000362248. Epub 2014 Aug 19. Urol Int. 2014. PMID: 25138778
-
Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients.World J Urol. 2018 Jul;36(7):1019-1029. doi: 10.1007/s00345-018-2235-5. Epub 2018 Feb 21. World J Urol. 2018. PMID: 29468284
-
Prognostic value of preoperative blood-based biomarkers in upper tract urothelial carcinoma treated with nephroureterectomy: A systematic review and meta-analysis.Urol Oncol. 2020 May;38(5):315-333. doi: 10.1016/j.urolonc.2020.01.015. Epub 2020 Feb 20. Urol Oncol. 2020. PMID: 32088103
Cited by
-
Is preoperative serum lactate dehydrogenase useful in predicting the outcomes of patients with upper tract urothelial carcinoma?Cancer Med. 2018 Oct;7(10):5096-5106. doi: 10.1002/cam4.1751. Epub 2018 Aug 27. Cancer Med. 2018. PMID: 30151961 Free PMC article.
-
Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab.In Vivo. 2021 Nov-Dec;35(6):3563-3568. doi: 10.21873/invivo.12659. In Vivo. 2021. PMID: 34697195 Free PMC article.
-
Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis.Sci Rep. 2015 Aug 3;5:12733. doi: 10.1038/srep12733. Sci Rep. 2015. PMID: 26235332 Free PMC article.
-
High expression of KPNA2 defines poor prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.BMC Cancer. 2015 May 9;15:380. doi: 10.1186/s12885-015-1369-8. BMC Cancer. 2015. PMID: 25956057 Free PMC article.
-
Blood-, Tissue- and Urine-Based Prognostic Biomarkers of Upper Tract Urothelial Carcinoma.Diagnostics (Basel). 2024 Aug 31;14(17):1927. doi: 10.3390/diagnostics14171927. Diagnostics (Basel). 2024. PMID: 39272712 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous